Maelstrom Research Staging | CKD-COVID19_CKD_patients_1_week_postdose

CKD-COVID19_CKD_patients_1_week_postdose_1

Networks -

Variables -

Associated study CKD-COVID19 Contingency Table

Population

CKD-COVID19 - CKD patients

The population is composed of individuals from Ontario and British Columbia at least 18 years of age with advanced chronic kidney disease (CKD) and received or plan to receive a COVID-19 vaccine. The safety and efficacy of COVID-19 vaccination are being observed in this population and are compared to observations in health care workers.

Selection Criteria

Minimum age

Newborns

Twins

Countries

Canada

Territory

Ethnic Origin

Health Status

Patients are diagnosed with chronic kidney disease (CKD) stage 3b, 4 or 5, defined as kidney function less than 45 mL/min and received or has agreed to receive a COVID-19 vaccine.

Other Criteria

Patients who have declined or plan to decline the COVID-19 vaccination are excluded from the study.

Recruitment

Sources of recruitment

Specific population

Specific Population

Clinic patients

Supplementary Information

Participants will be recruited from participating renal centers.

Number of Participants

Number of Participants

3,000

Number of Participants with Biological Samples

3,000

Supplementary Information about selection criteria

Hemodialysis patients: 1000 participants

Peritoneal dialysis patients: 500 participants

Non dialysis CKD patients: 1500 participants

More info

Data Collection Event

CKD-COVID19 - CKD patients - 1 week post-dose 1

Information is collected about adverse events following COVID-19 vaccination such as local reactions at the injection site and symptoms such as fever, chills, fatigue, nausea/vomiting, diarrhea, muscle pain, and joint pains.

More info

Collected Dataset / CKD-COVID19_CKD_patients_1_week_postdose_1

CKD-COVID19_CKD_patients_1_week_postdose_1

Population

CKD-COVID19 - CKD patients

Data Collection Event

CKD-COVID19 - CKD patients - 1 week post-dose 1

Files

Variables Classifications